^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Gastrointestinal Cancer |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Excerpt:
Mirati Therapeutics...announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
Source:
Title:
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Excerpt:
...- KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue or ctDNA....
Trial ID:
Source:
Title:
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Excerpt:
...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)...
Trial ID:
More C2 evidence
Source:
Title:
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Excerpt:
...Histologically confirmed diagnosis of a pancreatic cancer with KRAS G12C mutation....
Trial ID:
Source:
Title:
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Excerpt:
...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation...
Trial ID:
Source:
Title:
A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Excerpt:
...MRTX0902 and adagrasib combination therapy: KRAS G12C mutation....
Trial ID:
Source:
Title:
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Excerpt:
...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)...
Trial ID:
Less C2 evidence
Source:
Title:
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation
Published date:
01/18/2022
Excerpt:
KRYSTAL-1 (NCT03785249) is a multicohort Phase 1/2 study evaluating adagrasib as monotherapy or in combinations in pts with advanced solid tumors harboring a KRASG12C mutation. In a preliminary analysis, 27 pts with GI tumors were evaluable for clinical activity; partial responses (PRs) were seen in 41% (11/27, including 3 unconfirmed PRs); the disease control rate (DCR) was 100% (27/27). Of the 12 pts with PDAC...10 were evaluable for clinical activity; PRs were seen in 50% (5/10, including 1 unconfirmed PR); the DCR was 100% (10/10). Median progression-free survival (PFS) was 6.6 months (95% CI 1.0–9.7)...Adagrasib monotherapy is well tolerated and demonstrates encouraging clinical activity in pretreated pts with PDAC and other GI tumors harboring a KRASG12C mutation.
DOI:
10.1200/JCO.2022.40.4_suppl.519
Trial ID:
